2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4517 Real-world treatment patterns and outcomes over time of patients with high-grade B-cell lymphoma in a large US oncology network

Anthony Proli, PharmD, Yunzhi Qian, PhD2, Farhad Khan, MSPH3, Christoph Buhl, MD4, Ahmed Sawas, MD5
1 Flatiron Health, New York, New York, United States
2 Flatiron Health, Durham, North Carolina, United States
3 Flatiron Health, New York, New York, United States
4 Flatiron Health GmbH, Berlin, Germany
5 Flatiron Health, New York, New York, United States

Introduction: High-grade B-cell lymphoma (HGBCL) is a rare and aggressive lymphoma type introduced in the World Health Organization classification in 2016. The treatment for HGBCL is heterogeneous due to its rarity, and there is no standard of care frontline or salvage therapy. Several novel therapeutics have been approved for large B-cell lymphoma (LBCL) over the past 10 years, including chimeric antigen receptor T-cell therapy (CAR T) and bispecific antibodies, and the uptake and effect of these treatments on outcomes in this population are undefined. The objective of this study is to describe the clinical characteristics, real-world treatment patterns, and associated outcomes of HGBCL patients (pts) diagnosed in 2 eras: 2016 through 2021 and 2022 through 2026. 

Methods: This retrospective cohort study used pt-level data from >82,000 pts with LBCL in the US-based, electronic health record (EHR)-derived, deidentified Flatiron Health Research Database. Pts with a diagnosis of HGBCL with MYC and B-cell lymphoma (BCL)2 and/or BCL6 rearrangements, or HGBCL, not otherwise specified (NOS) between January 1, 2016 and April 30, 2026, were included. Diagnostic categories reflected terminology documented in the EHR during the study period. Pts were stratified into 2 eras by diagnosis date. Early-era (E-era) was defined as January 1, 2016 through December 31, 2021, and Late-era (L-era) was defined as January 1, 2022 through April 30, 2026. Baseline demographics, clinical characteristics, and treatment patterns were analyzed using descriptive statistics. Real-world overall survival (rwOS) and real-world progression free survival (rwPFS) were analyzed for a first-line (1L) treated population, indexed to treatment initiation, using Kaplan-Meier methods. Median follow-up was estimated and reported separately by era.

Results: A total of 3964 pts with HGBCL were included, with 2199 in the E-era, and 1765 in the L-era. There were no major demographic differences between the eras. The median age at diagnosis was 70 (61-77) years and 58% of pts were male. Overall, 25% of the cohort was treated at an academic center, and 69% treated in the community. Pts with HGBCL with MYC and BCL2 and/or BCL6 rearrangements comprised 76% (n=3000) of the cohort, and 24% (n=964) HGBCL, NOS. Of pts with documented stage, 78% had stage III/IV disease. Overall, 3620 (91%) had evidence of receiving at least 1 line of therapy, with 2229 (56%) having 1L only, 752 (19%) with second-line, and 639 (16%) with third-line or later therapy. The most common 1L treatments in both the E-era and L-era were R-CHOP in 29% (n=586) and 29% (n=459), respectively; R-EPOCH, used in 18% (n=363) and 20% (n=315), respectively; and R-EPOCH + MTX, used in 20% (n=396) and 15% (n=235), respectively. Pola-R-CHP was used in 4.2% (n=67) of L-era pts. In pts receiving second-line or subsequent therapy, the most common treatment in both eras was chemoimmunotherapy in 34% (n=608) of E-era, and 27% (n=286) of L-era pts. Hematopoietic cell transplantation (HCT) use differed between the 2 eras with more E-era pts (n=91; 5.1%) compared with L-era pts (n=15; 1.4%) undergoing HCT. CAR T use was more common in the L-era (n=148; 14%) versus E-era (n=128; 7.1%). There was also increased use of bispecific therapies in the Late (n=116; 11%) vs Early (n=18; 1.0%) era. Later-line treatment categories were not mutually exclusive. With a median follow-up time of 14.77 months, the median rwOS for the entire 1L-treated cohort was 51.06 months (95% CI, 43.96-59.27), and there was no observed difference in median rwOS between E-era (50.83 mo; 95% CI, 42.87-60.19) and L-era (not reported [NR]; 95% CI, 39.72-NR). Median 1L rwPFS overall was 20.07 months (95% CI, 17.08-24.51). The 3-year landmark rwOS and rwPFS were 54% and 45% in the E-era, and 55% and 42% in the L-era, respectively. 

Conclusions: In this large US-based HGBCL cohort, frontline treatment changed little after 2022, whereas later-line care shifted away from HCT and toward CAR T and bispecific antibodies. Despite these changes, rwOS and rwPFS appeared similar between the E-era and L-era in descriptive analysis. Interpretation was limited by shorter follow-up in the L-era and potential changes in disease classification over time. These findings highlight persistent unmet need and support further evaluation of outcomes by molecular subtype, optimal 1L treatment, and sequencing of novel therapies in relapsed HGBCL.

Anthony Proli, PharmD: Pfizer - Current equity holder in publicly-traded company; Roche - Current equity holder in publicly-traded company; Flatiron Health, Inc. - Research Funding; Flatiron Health, Inc. - Current Employment